ArticleMediators of inflammation2026
FGFR2 is a Candidate Immune-Associated Marker of Diabetic Foot Ulcer That Promotes Keratinocyte Function by Activating the PI3K/Akt and MAPK Pathways.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hsa_circ_0006969 aggravates keratinocytes from high-glucose injury by sponging miR-375 to promote USP10 and SCD expression.Functional & integrative genomics · 2026Article
- FGFR2 is a Candidate Immune-Associated Marker of Diabetic Foot Ulcer That Promotes Keratinocyte Function by Activating the PI3K/Akt and MAPK Pathways.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDiabetic foot ulcer (DFU) is a serious complication of diabetes. This study aims to screen DFU-associated immune-related genes (IRGs) and investigate their potential functional mechanisms and clinical relevance.
methodsBased on the GSE80178 dataset, the differentially expressed genes (DEGs) between DFU and diabetic foot skin (DFS) were screened out and cross-linked with IRGs to obtain differentially expressed IRGs (DE-IRGs). Functional enrichment analysis was conducted using the "clusterProfiler" R package. The protein-protein interaction (PPI) network was constructed using the STRING platform, and the core genes were identified based on topological analysis. The expression and diagnostic efficacy of core genes were verified using external datasets (GSE199939 and GSE134431). Immune cell infiltration analysis was performed using CIBERSORT algorithm. The candidate drugs were predicted through the L1000FWD database and molecular docking was carried out with Autodock Vina. The function of the core gene and its molecular mechanism were verified by constructing a high glucose (HG)-induced HaCaT cell injury model in vitro.
resultsA total of 108 DE-IRGs were screened out, including 48 upregulated genes and 60 downregulated genes. These genes were significantly enriched in the cytokine-cytokine receptor interaction, phosphoinositol 3-kinase (PI3K)-protein kinase B (Akt) and mitogen-activated protein kinase (MAPK) signaling pathways. Fibroblast growth factor receptor (FGFR) 2 was identified as the core gene, and its expression was significantly downregulated in DFU, with high diagnostic value (area under the curve [AUC] >0.95). The expression of FGFR2 was correlated with the infiltration levels of various immune cells. QL-XI-92, reversine, BRD-K67414432, LY294002, and neratinib had high binding affinity with the FGFR2 protein. HG significantly reduced the expression of FGFR2 in HaCaT cells, inhibited proliferation and migration, and promoted apoptosis and the secretion of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β and IL-6; overexpression of FGFR2 reversed the above-mentioned phenomena and activated the PI3K/Akt and p38 MAPK pathways. The protective effect of FGFR2 could be reversed by LY294002 (an inhibitor of PI3K/Akt pathway) or SB202190 (a p38 MAPK inhibitor).
conclusionFGFR2 is lowly expressed in DFU and can exert a protective effect by activating the PI3K/Akt pathway. It is a candidate diagnostic biomarker and potential therapeutic target for DFU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.